lifestyle.longislandreport.org

Author: Mabwell (Shanghai) Bioscience Co., Ltd.

Mabwell Establishes a Licensing and Commercialization Agreement for Denosumab Biosimilars in Malaysian Market

April 16, 2026
Global First | NMPA Accepts IND Application for Mabwell’s Innovative LILRB4/CD3 TCE Bispecific Antibody 6MW5311

April 15, 2026
Mabwell Announces Acceptance of Supplemental Biologics License Application by NMPA for MAIWEIJIAN (Denosumab)

April 15, 2026
SST001, an α-syn PET tracer from Mabwell’s incubated company SynuSight Biotech, received NMPA approval to initiate a clinical trial

April 14, 2026
Mabwell Announces First-Patient Dosed in Clinical Trial of Novel CDH17-Targeting ADC 7MW4911 in the U.S.

January 22, 2026
Mabwell’s Adalimumab Biosimilar Receives Marketing Approval in Indonesia

December 31, 2025
Mabwell Announces First Patient Dosed in Phase II Trial of Anti-IL-11 Antibody for Pathological Scarring

December 30, 2025
Mabwell Receives IND Clearance for Novel Anti-ST2 Monoclonal Antibody 9MW1911 to Initiate Phase IIa Study

December 24, 2025
Mabwell Announces First Overseas Commercial Shipment of Denosumab Injection

December 17, 2025
Annualized Severe COPD Exacerbation Rate Reduced by Over 40%: Mabwell Announces Phase IIa Results for Innovative Anti-ST2 Antibody 9MW1911

December 1, 2025